Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR407899 in microvascular angina or persistent stable angina after successful PCI
NL-OMON46635Phase 2Withdrawn
- Sponsor
- Sanofi
- Start
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in microvascular angina (MVA) and stable angina comparing SAR407899 with Placebo (2 arms). Primary endpoint: Change from baseline to Week 4 in uncorrected global coronary flow reserve. Planned start Jun 2017; status: withdrawn.
02
Drugs
SAR407899
03
Conditions
microvascular angina (MVA)stable angina
Beyond the preview
Go deeper on NL-OMON46635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46635.